Santen Pharmaceutical Co., Ltd.

Boehringer Ingelheim International Gmbh

Kenji Oki

Takashi Nagano

Koushi Fujisawa

Nagayoshi Asano

Toshiyuki Mori

Masatomo Kato

Mamoru Matsuda

Miwa Takai

Masaaki Murai

Takahiro Matsuyama

Tatsuji Kurose

Yumi Hagiwara

Fumio Tsuji

Chikako Setoguchi

Iwao Seki

Minoru Sasano

A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. A method of preventing and/or treating dry eye in a subject in need thereof, comprising administering a therapeutically effective amount of olodaterol or a salt thereof to the subject is also provided.

Medicament for preventing and/or treating dry eye

A method for treating a TRPV1-mediated disease by administering to a patient a therapeutically effective amount of a compound or a salt thereof having the following formula [I]: wherein A represents a lower alkylene group or a lower alkenylene group; Rrepresents a hydrogen atom, an unsubstituted or substituted alkyl group or an unsubstituted or substituted alkenyl group; and Rand Rare the same or different and represent a hydrogen atom, an unsubstituted lower alkyl group or a lower alkyl group substituted by a monocyclic cycloalkyl group, a polycyclic cycloalkyl group or an aryl group.

Method for treating a TRPV1-mediated disease

The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as a therapeutic agent for diseases against which a glucocorticoid receptor agonist (e.g., a steroid) is believed to be effective, such as inflammatory bone/joint diseases, inflammatory ophthalmic diseases (inflammatory ophthalmic diseases in the anterior or posterior segment of an eye). Rrepresents a group represented by general formula (2a), (3a), (4a) or (5a); Rrepresents a lower alkyl group which may have a substituent, a lower cycloalkyl group which may have a substituent, or the like; Rrepresents a lower alkyl group; R, R, Ror Rrepresent a halogen atom, a lower alkyl group which may have a substituent, a hydroxy group, a lower alkoxy group which may have a substituent, or the like; and m, n, p or q represents a number of 0, 1 or 2. 

Method for treating an inflammatory disease by administering a 1,2,3,4- tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituent

Growing community of inventors

Ikoma, Japan

Kenji Oki